HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 41,709 shares, a decrease of 85.9% from the June 15th total of 296,814 shares. Based on an average trading volume of 197,573 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.9% of the company’s shares are short sold.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on HCWB shares. Wall Street Zen upgraded HCW Biologics to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a report on Tuesday, April 21st. Finally, Maxim Group lifted their price target on shares of HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.00.
Check Out Our Latest Report on HCW Biologics
Insider Activity
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent filing with the SEC. 2.96% of the stock is currently owned by institutional investors and hedge funds.
HCW Biologics Stock Performance
NASDAQ HCWB traded down $0.09 on Friday, reaching $4.55. The company had a trading volume of 30,582 shares, compared to its average volume of 130,137. The company’s fifty day moving average is $7.24 and its 200-day moving average is $5.63. The firm has a market capitalization of $7.28 million, a price-to-earnings ratio of -0.08 and a beta of 2.29. HCW Biologics has a 1-year low of $1.50 and a 1-year high of $44.10.
HCW Biologics (NASDAQ:HCWB – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $3.01. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.The firm had revenue of $6.54 million for the quarter, compared to the consensus estimate of $6.54 million.
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Featured Stories
- Five stocks we like better than HCW Biologics
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
